Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 596

1.

Immunobiology of cholangiocarcinoma.

Loeuillard E, Conboy CB, Gores GJ, Rizvi S.

JHEP Rep. 2019 Jul 10;1(4):297-311. doi: 10.1016/j.jhepr.2019.06.003. eCollection 2019 Oct. Review.

2.

Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complication.

Tan EK, Rosen CB, Heimbach JK, Gores GJ, Zamora-Valdes D, Taner T.

J Am Coll Surg. 2020 Feb 5. pii: S1072-7515(20)30127-7. doi: 10.1016/j.jamcollsurg.2019.12.037. [Epub ahead of print]

PMID:
32035181
3.

Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis.

Hirsova P, Bohm F, Dohnalkova E, Nozickova B, Heikenwalder M, Gores GJ, Weber A.

Cell Death Dis. 2020 Feb 3;11(2):80. doi: 10.1038/s41419-020-2283-9.

4.

Systemic therapies for intrahepatic cholangiocarcinoma.

Kelley RK, Bridgewater J, Gores GJ, Zhu AX.

J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009. Review.

PMID:
31954497
5.

Phenotypic, transcriptional and functional analysis of liver mesenchymal stromal cells and their immunomodulatory properties.

Taner T, Abrol N, Park WD, Hansen MJ, Gustafson MP, Lerman LO, van Wijnen AJ, Dietz AB, Gores GJ, Stegall MD.

Liver Transpl. 2020 Jan 16. doi: 10.1002/lt.25718. [Epub ahead of print]

PMID:
31950576
6.

An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.

Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, Gossard AA, Lazaridis KN, Lindor KD, Eaton JE.

J Gastroenterol. 2020 Jan 13. doi: 10.1007/s00535-020-01663-1. [Epub ahead of print]

PMID:
31932891
7.

Reply to letter.

Yang JD, Mara KC, Gores GJ, Roberts LR.

Hepatology. 2020 Jan 4. doi: 10.1002/hep.31098. [Epub ahead of print]

PMID:
31901172
8.

Reply to letter.

Yang JD, Mara KC, Gores GJ, Roberts LR.

Hepatology. 2020 Jan 4. doi: 10.1002/hep.31097. [Epub ahead of print]

PMID:
31901147
9.

EUS-FNA is effective for lymph node staging in patients with cholangiocarcinoma.

Malikowski T, Levy MJ, Gleeson FC, Storm AC, Vargas Valls EJ, Topazian MD, Abu Dayyeh BK, Iyer PG, Rajan E, Gores GJ, Roberts L, Chandrasekhara V.

Hepatology. 2019 Dec 20. doi: 10.1002/hep.31077. [Epub ahead of print]

PMID:
31860935
10.

The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis.

Guicciardi ME, Trussoni CE, LaRusso NF, Gores GJ.

Hepatology. 2020 Feb;71(2):741-748. doi: 10.1002/hep.31067. Review.

PMID:
31833071
11.

An Open Label, Dose Escalation Study To Assess The Safety And Efficacy Of IL-22 Agonist F-652 In Patients With Alcoholic Hepatitis.

Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, Dreyer K, Yan X, Daley WL, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores GJ, Malhi H, Kamath PS, Shah VH.

Hepatology. 2019 Nov 27. doi: 10.1002/hep.31046. [Epub ahead of print]

PMID:
31774566
12.

Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration.

Roddy GW, Rosa RH, Viker KB, Holman BH, Hann CR, Krishnan A, Gores GJ, Bakri SJ, Fautsch MP.

Curr Eye Res. 2019 Dec 2:1-7. doi: 10.1080/02713683.2019.1694156. [Epub ahead of print]

PMID:
31735070
13.

Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis.

Eaton JE, Sen A, Hoodeshenas S, Schleck CD, Harmsen WS, Gores GJ, LaRusso NF, Gossard AA, Lazaridis KN, Venkatesh SK.

Clin Gastroenterol Hepatol. 2019 Nov 1. pii: S1542-3565(19)31243-1. doi: 10.1016/j.cgh.2019.10.041. [Epub ahead of print]

PMID:
31683058
14.

The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1.

O'Hara SP, Splinter PL, Trussoni CE, Guicciardi ME, Splinter NP, Al Suraih MS, Nasser-Ghodsi N, Stollenwerk D, Gores GJ, LaRusso NF.

J Biol Chem. 2019 Dec 6;294(49):18698-18713. doi: 10.1074/jbc.RA119.010176. Epub 2019 Oct 28.

PMID:
31659122
15.

The Two Faces of Relaxin in Cancer: Antitumor or Protumor?

Rizvi S, Gores GJ.

Hepatology. 2019 Oct 20. doi: 10.1002/hep.30998. [Epub ahead of print]

PMID:
31630431
16.

Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC.

Kaura K, Sawas T, Bazerbachi F, Storm AC, Martin JA, Gores GJ, Abu Dayyeh BK, Topazian MD, Levy MJ, Petersen BT, Chandrasekhara V.

Dig Dis Sci. 2019 Sep 30. doi: 10.1007/s10620-019-05866-2. [Epub ahead of print]

PMID:
31571103
17.

A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR.

Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22. Review.

18.

Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11.

Katsumi T, Guicciardi ME, Azad A, Bronk SF, Krishnan A, Gores GJ.

Am J Physiol Cell Physiol. 2019 Oct 1;317(4):C788-C799. doi: 10.1152/ajpcell.00250.2019. Epub 2019 Jul 31.

PMID:
31365294
19.

Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.

Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.

Hepatology. 2019 Jul 15. doi: 10.1002/hep.30858. [Epub ahead of print]

PMID:
31309602
20.

The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies with Implications for Hepatobiliary Malignancies.

Werneburg N, Gores GJ, Smoot RL.

Gene Expr. 2019 Jun 28. doi: 10.3727/105221619X15617324583639. [Epub ahead of print]

PMID:
31253203
21.

Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch.

Eaton JE, Gores GJ.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):417-418. doi: 10.1016/S2468-1253(19)30084-6. Epub 2019 Mar 26. No abstract available.

PMID:
30922872
22.

Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice.

Aziz K, Limzerwala JF, Sturmlechner I, Hurley E, Zhang C, Jeganathan KB, Nelson G, Bronk S, Fierro Velasco RO, van Deursen EJ, O'Brien DR, Kocher JA, Youssef SA, van Ree JH, de Bruin A, van den Bos H, Spierings DCJ, Foijer F, van de Sluis B, Roberts LR, Gores GJ, Li H, van Deursen JM.

Gastroenterology. 2019 Jul;157(1):210-226.e12. doi: 10.1053/j.gastro.2019.03.016. Epub 2019 Mar 13.

PMID:
30878468
23.

Cholangiocyte pathobiology.

Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ.

Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-281. doi: 10.1038/s41575-019-0125-y. Review.

24.

Hedgehog Signaling Modulates Interleukin-33-Dependent Extrahepatic Bile Duct Cell Proliferation in Mice.

Razumilava N, Shiota J, Mohamad Zaki NH, Ocadiz-Ruiz R, Cieslak CM, Zakharia K, Allen BL, Gores GJ, Samuelson LC, Merchant JL.

Hepatol Commun. 2018 Dec 11;3(2):277-292. doi: 10.1002/hep4.1295. eCollection 2019 Feb.

25.

Translation to Practice: Accelerating the Cycle of Innovation to Impact.

Anderson JR, Chung TDY, Clark L, Weis JA, Danielsen AJ, Khosla S, Gores GJ, Badley AD.

Mayo Clin Proc. 2019 Mar;94(3):490-499. doi: 10.1016/j.mayocp.2018.08.008. Epub 2019 Feb 7. Review.

26.

GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.

Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281. Epub 2018 Nov 21.

PMID:
30464023
27.

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX.

Hepatology. 2019 Apr;69(4):1803-1815. doi: 10.1002/hep.30289. Epub 2019 Mar 25. Review.

PMID:
30251463
28.

YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.

Sugihara T, Werneburg NW, Hernandez MC, Yang L, Kabashima A, Hirsova P, Yohanathan L, Sosa C, Truty MJ, Vasmatzis G, Gores GJ, Smoot RL.

Mol Cancer Res. 2018 Oct;16(10):1556-1567. doi: 10.1158/1541-7786.MCR-18-0158. Epub 2018 Jun 14.

29.

Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma.

Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ.

Semin Liver Dis. 2018 May;38(2):160-169. doi: 10.1055/s-0038-1655775. Epub 2018 Jun 5. Review.

30.

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.

Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ.

J Hepatol. 2018 Sep;69(3):676-686. doi: 10.1016/j.jhep.2018.05.018. Epub 2018 May 24.

31.

Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.

Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.

Hepatology. 2020 Jan;71(1):214-224. doi: 10.1002/hep.30085. Epub 2018 Dec 28.

32.

Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened.

Rizvi S, Gores GJ.

Hepatology. 2018 Dec;68(6):2428-2430. doi: 10.1002/hep.30069. Epub 2018 Nov 7. No abstract available.

33.

Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?

Yang JD, Gores GJ.

Hepatology. 2018 Oct;68(4):1217-1219. doi: 10.1002/hep.30063. Epub 2018 Jul 10. No abstract available.

34.

Animal models of cholangiocarcinoma.

Loeuillard E, Fischbach SR, Gores GJ, Rizvi S.

Biochim Biophys Acta Mol Basis Dis. 2019 May 1;1865(5):982-992. doi: 10.1016/j.bbadis.2018.03.026. Epub 2018 Apr 5. Review.

PMID:
29627364
35.

YAP-associated chromosomal instability and cholangiocarcinoma in mice.

Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ.

Oncotarget. 2017 Dec 22;9(5):5892-5905. doi: 10.18632/oncotarget.23638. eCollection 2018 Jan 19.

36.

Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.

Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ.

J Hepatol. 2018 Jun;68(6):1228-1238. doi: 10.1016/j.jhep.2018.01.026. Epub 2018 Mar 9.

37.

Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.

Ibrahim SH, Hirsova P, Gores GJ.

Gut. 2018 May;67(5):963-972. doi: 10.1136/gutjnl-2017-315691. Epub 2018 Jan 24. Review.

38.

TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity.

Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, Gores GJ.

Hepatol Commun. 2017 Sep;1(7):648-662. doi: 10.1002/hep4.1069. Epub 2017 Jul 20.

39.

The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.

Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ; TREAT Consortium.

Hepatology. 2018 Apr;67(4):1284-1302. doi: 10.1002/hep.29623. Epub 2018 Feb 22.

40.

Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.

Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR.

Hepatology. 2018 Jul;68(1):78-88. doi: 10.1002/hep.29594. Epub 2018 May 9.

41.

Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ.

Nat Rev Clin Oncol. 2018 Feb;15(2):95-111. doi: 10.1038/nrclinonc.2017.157. Epub 2017 Oct 10. Review.

42.

Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know.

Gossard AA, Gores GJ.

Clin Liver Dis. 2017 Nov;21(4):725-737. doi: 10.1016/j.cld.2017.06.004. Epub 2017 Jul 25. Review.

PMID:
28987259
43.

Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis.

Loarca L, De Assuncao TM, Jalan-Sakrikar N, Bronk S, Krishnan A, Huang B, Morton L, Trussoni C, Bonilla LM, Krueger E, O'Hara S, Splinter P, Shi G, Pisarello MJL, Gores GJ, Huebert RC, LaRusso NF.

Lab Invest. 2017 Nov;97(11):1385-1396. doi: 10.1038/labinvest.2017.63. Epub 2017 Sep 11.

44.

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Greuter T, Malhi H, Gores GJ, Shah VH.

JCI Insight. 2017 Sep 7;2(17). pii: 95354. doi: 10.1172/jci.insight.95354. eCollection 2017 Sep 7. Review.

45.

Targeting cholangiocarcinoma.

Mertens JC, Rizvi S, Gores GJ.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24. Review.

46.

PPAR agonists for primary biliary cholangitis.

Gossard AA, Gores GJ.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):693-694. doi: 10.1016/S2468-1253(17)30256-X. Epub 2017 Aug 14. No abstract available.

PMID:
28818517
47.

Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC.

Hepatology. 2018 Jan;67(1):247-259. doi: 10.1002/hep.29464. Epub 2017 Nov 29.

48.

Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.

Smoot RL, Werneburg NW, Sugihara T, Hernandez MC, Yang L, Mehner C, Graham RP, Bronk SF, Truty MJ, Gores GJ.

J Cell Biochem. 2018 Jan;119(1):824-836. doi: 10.1002/jcb.26246. Epub 2017 Aug 3.

49.

Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death.

Liu Y, Verma VK, Malhi H, Gores GJ, Kamath PS, Sanyal A, Chalasani N, Gao B, Shah VH.

Am J Physiol Cell Physiol. 2017 Sep 1;313(3):C305-C313. doi: 10.1152/ajpcell.00005.2017. Epub 2017 Jun 21.

50.

Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma.

Ramanan P, Cummins NW, Wilhelm MP, Heimbach JK, Dierkhising R, Kremers WK, Rosen CB, Gores GJ, Razonable RR.

Clin Transplant. 2017 Aug;31(8). doi: 10.1111/ctr.13023. Epub 2017 Jul 5.

PMID:
28573685

Supplemental Content

Loading ...
Support Center